Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Among patients with hematologic malignancies, including MPNs, higher rates of mortality due to COVID-19 than the general public were reported in a poster presented during the ESMO Congress 2021. Thirty-day all-cause mortality among all patients in the study was 19%, with 83% of these deaths attributable to COVID-19 complications. Patients with chronic MPNs had one of the highest rates (100%) of detectable immunoglobulin IgG to SARS-CoV-2 antibody among patients with other hematologic malignancies.